Skip to Main Content

A Study to Assess the Genotype of Subjects with Diagnosis of Ulcerative Colitis or Crohn's Disease (The PRELUDE Study)

  • Study HIC#:2000031352
  • Last Updated:11/11/2022

Researchers are trying to develop a more targeted approach to treat ulcerative colitis (UC) and Crohn’s disease (CD). This research study will help develop tests that may indicate how well patients will respond to different therapies in the future.

 Your participation in this study is expected to last from 1 to 35 days and is expected to include 1 to 2 study visits to the study center. If the original sample(s) you provide are not usable, you will be asked to provide additional sample(s). You will not be asked to provide more than one additional sample.

  • Age18 years and older
  • GenderBoth
  • Start Date11/10/2021
  • End Date12/31/2022

Trial Purpose and Description

Researchers are trying to develop a more targeted approach to treat ulcerative colitis (UC) and Crohn’s disease (CD). This research study will help develop tests that may indicate how well patients will respond to different therapies in the future. 

Your participation in this study is expected to last from 1 to 35 days and is expected to include 1 to 2 study visits to the study center. If the original sample(s) you provide are not usable, you will be asked to provide additional sample(s). You will not be asked to provide more than one additional sample.

Eligibility Criteria

Inclusion Criteria:

1. Male or female and aged ≥ 18. 

2. Diagnosis of ulcerative colitis (UC) or Crohn’s disease (CD) established prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report. 

3. Currently on at least 1 approved therapy for UC or CD

Principal Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: